Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
The current Johnson & Johnson(JNJ) stock price is $270.69, with a market capitalization of 652.48B. The stock trades at a price-to-earnings (P/E) ratio of 31.20 and offers a dividend yield of 1.96%.
During the trading session on 2026-09-24, Johnson & Johnson(JNJ) shares reached a daily high of $275.23 and a low of $269.01. At a current price of $270.69, the stock is +0.6% higher than the low and still -1.6% under the high.
Trading volume for Johnson & Johnson(JNJ) stock has reached 6.32M, versus its average volume of 6.44M.
Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $281.07 and a low of $175.74.
Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $281.07 and a low of $175.74.
JNJ News
...
Investing CDs Offer Certainty. Dividend Stocks Offer Something Retirees May Need More When a retiree compares a federally insured CD to a dividend stock that ha...
Key Points Bristol Myers Squibb maintains a robust specialized drug portfolio and generates strong free cash flow to support its operations. Johnson & Johnson...
Analyst ratings
70%
of 27 ratingsMore JNJ News
has delivered a powerful run over the past few years, and with the stock now near US$269, investors are increasingly asking whether that price is fully backed b...
Johnson & Johnson announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI plus DARZALEX FASPRO in pati...
Analyst Michael Yee from UBS maintained a Buy rating on Johnson & Johnson and keeping the price target at $320.00. Michael Yee has given his Buy rating due to...
Johnson & Johnson (JNJ) is back in focus after new Phase 3 data for Caplyta in bipolar I mania, with investors weighing how this potential label expansion inter...
Key Points Johnson & Johnson announced plans to spin off its orthopedics business in late 2025. In early 2026, J&J was reported to be in talks with private eq...
The Investing Playbook for Retirees Who Can't Afford to Lose Key Points Remaining diversified is one of the best ways to reduce risk. A cash fund can prevent y...
Johnson & Johnson announced topline results from the Phase 3 study evaluating Caplyta for the treatment of manic episodes with or without mixed features in adul...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.